Anebulo Pharmaceuticals Inc Sustainability Reports
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing therapies for cannabis-induced toxicity. Its lead product candidate, selonabant, is being developed as an antidote for acute cannabinoid intoxication and unintentional cannabis poisoning.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
LEI: 549300XYJQJDSQZ0AY81
FIGI: BBG00ZWY5GD7
2 reports from 2023 to 2024
